Character Biosciences at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

Character Biosciences at ASHG 2026 in Montréal: 1 presentation (1 poster).

Organization	ASHG 2026 Attendance
Character Biosciences	1 Research Associate
characterbio.com\|LinkedIn Character Bio develops targeted therapeutics for progressive polygenic eye diseases. It focuses on patients with age-related macular degeneration and primary open-angle glaucoma. Presented three research abstracts at the ARVO 2026 ophthalmology conference, a routine scientific visibility event. › Presented three research abstracts at the ARVO 2026 ophthalmology conference, a routine scientific visibility event. 2026-05 · source Was named a Fierce 15 biotech company for its precision-ophthalmology approach, an industry recognition. 2025-09 · source Expanded its leadership team and extended its Series B round to more than $110 million total. 2025-09 · source Source: company newsroom Series B extended to over $110M total (Sep 2025) › Sanofi Ventures participated in the round; lead investors for the extension were not named. · 2025-09-17 “The company also announced an expansion of its Series B financing, bringing total capital raised in the round to more than $110 million.” Source: funding announcement Currently hiring: 3 open roles › Source: careers page	Poster Thu Oct 22 4:15 pm Part of Statistical Genetics and Genetic Epidemiology Poster Thursday Session Retina-specific functional annotations enhance gene prioritization for AMD progression genetic associations Exhibit & Poster Hall · Board 8443T Statistical geneticsGenome-wide association studyVariant interpretationPhenotype

Organization

ASHG 2026 Attendance

Character Biosciences

1 Research Associate

characterbio.com|LinkedIn

Character Bio develops targeted therapeutics for progressive polygenic eye diseases. It focuses on patients with age-related macular degeneration and primary open-angle glaucoma.

Presented three research abstracts at the ARVO 2026 ophthalmology conference, a routine scientific visibility event.

›

Presented three research abstracts at the ARVO 2026 ophthalmology conference, a routine scientific visibility event.

2026-05 · source

Was named a Fierce 15 biotech company for its precision-ophthalmology approach, an industry recognition.

2025-09 · source

Expanded its leadership team and extended its Series B round to more than $110 million total.

2025-09 · source

Source: company newsroom

Series B extended to over $110M total (Sep 2025)

›

Sanofi Ventures participated in the round; lead investors for the extension were not named. · 2025-09-17

“The company also announced an expansion of its Series B financing, bringing total capital raised in the round to more than $110 million.”

Source: funding announcement

Currently hiring: 3 open roles

›

Source: careers page

Poster

Thu Oct 22
4:15 pm

Part of Statistical Genetics and Genetic Epidemiology Poster Thursday Session

Retina-specific functional annotations enhance gene prioritization for AMD progression genetic associations

Exhibit & Poster Hall · Board 8443T

Statistical geneticsGenome-wide association studyVariant interpretationPhenotype

Instantly find 20 buyers from Character Biosciences

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction